Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deoxyuridine triphosphatase (dUTPase) is an enzyme crucial for maintaining genomic integrity by hydrolyzing dUTP into dUMP and pyrophosphate. This prevents the incorporation of uracil into DNA during replication and repair, and provides dUMP for thymidine nucleotide synthesis. dUTPase exists as a homotrimer and has both nuclear and mitochondrial isoforms, each serving distinct roles in genome stability. Due to its essential role in nucleotide metabolism, dUTPase is considered a potential drug target, particularly in cancer therapy, where inhibition may disrupt nucleotide balance and sensitize cells to treatment.
Inhibition of dUTPase activity to disrupt nucleotide balance and promote uracil misincorporation into DNA, potentially leading to cytotoxicity or enhanced sensitivity to chemotherapeutic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deoxyuridine triphosphatase (dUTPase).